Stock · Healthcare
BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has a solid dividend profile with no major red flags in the snapshot data.
Why we rate it 6.8
- Yield of 4.06% is on the higher end but historically sustainable for REITs and quality income payers
- Payout ratio of 70% is on the higher side — leaves less buffer for earnings volatility
- Current yield is in line with the 5-year average of 3.96%
- Large-cap scale (>$50B) — established business with predictable cash flows
Where BMY ranks
We compute the same 0–10 safety score across 154dividend-paying stocks and ETFs. Here's where BMY lands inside that universe.
The universe is curated to the most-searched US dividend payers. We'll expand it as the data layer grows; sector percentiles only appear when we have at least 5 comparable peers.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
How we score dividend safety
The Infnits Dividend Safety Score is a 0–10 rating derived from yield zone, payout ratio (when applicable), yield trend versus 5-year average, instrument type, and company size. Each factor is independently transparent — see the reasons above for exactly which factors contributed to BMY's score.
For the full methodology including the in-app version that uses ETF look-through and historical cut data, see our methodology page.
This is educational, not investment advice.Dividend safety scores reflect a snapshot of public data on the "as of" date shown. Verify current data on the issuer's investor relations page or your brokerage before making decisions.
Frequently asked questions
Is BMY's dividend safe?
Based on snapshot data — yield 4.06%, payout ratio 70%, instrument type stock — Infnits rates BMY's dividend safety profile as solid (6.8/10). This is one signal, not a recommendation.
What is BMY's current dividend yield?
BMY has a current dividend yield of 4.06% as of July 26, 2026. Its 5-year average yield is 3.96%.
How is BMY's safety score calculated?
The score combines yield zone (yields above 7% historically carry elevated cut risk), payout ratio (lower is safer), trend vs. 5-year average yield, instrument type (ETFs are inherently more diversified), and size (larger companies have more stable cash flows). Each factor is scored 0-2.5 and summed to a 0-10 result.
Where does this data come from?
Fundamentals are sourced from public market data and refreshed regularly. The "as of" date on each page reflects the snapshot used for the score. For real-time data, check the issuer's investor relations page or your brokerage.
Should I buy BMY based on this score?
No — this is an educational score based on a handful of public signals, not investment advice. Use it as one input among many. For a portfolio-aware analysis with ETF look-through and personalized insights, install the Infnits app.
Get emailed when BMY score changes.
BMY head-to-head comparisons
See BMY compared side-by-side with the most-searched peer tickers — yield, safety, growth trend, expense ratio, and tax treatment.
Other dividend tickers
Track your full portfolio's dividend safety
Connect your brokerage in the Infnits app and get a portfolio-wide safety score with ETF look-through, concentration analysis, and AI-generated insights — updated daily.